Navigation Links
NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan

SOPHIA ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. A preliminary analysis of 11 patients from this proof-of-concept study in portal hypertension confirmed the safety profile of NCX 1000 but did not demonstrate the efficacy required to support the continuation of this clinical trial. As a consequence, Axcan and NicOx have agreed not to further pursue the development of NCX 1000 and to terminate the trial.

The trial was a phase 2a, double-blind, dose-escalating proof-of-concept study in which 11 patients with portal hypertension were enrolled in a single clinical center in Spain. Portal hypertension is abnormally raised blood pressure in the portal vein, which carries blood from the digestive system to the liver (see NOTE). Patients were randomized to receive either placebo or escalating doses of NCX 1000 (500mg, 1000mg and 2000mg as the first three doses during the first two days). This was followed by 2000mg (or the maximum tolerated dose) three times a day for the following 14 days.

The primary endpoint of the trial was defined as the comparison between patients' portal pressure in the fasting state on day 16 of treatment with the corresponding baseline values. A secondary endpoint was the same comparison following the consumption of a controlled meal and additional endpoints were based on the response rate (defined in terms of portal pressure reduction), the increase in liver blood flow, clinical safety, tolerability and pharmacokinet ics.

NCX 1000 showed good safety and tolerability, confirming the results observed in two previous phase 1 studies, and NicOx and Axcan will now proceed with further data analysis and full results will be disclosed at a later date.

Maarten Beekman, Vice President of Clinical Devel
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NicOx Provides Update the Phase Study for NCX Conducted With Axcan
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... May 25 Two late-breaking clinical trials presented ... clinical data supporting Abbott,s market-leading XIENCE V® Everolimus Eluting ... of more than 5,000 real-world, complex patients, XIENCE V ... at one year (0.84 percent per Academic Research Consortium ...
... 24 At a town hall meeting a year ago, President Obama ... by keeping older people out of more expensive institutional care.  "I actually think ... it helps keep people in their homes," the president told his audience in ... , , ...
Cached Medicine Technology:New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 2New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 3New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 4New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 5Medicare Policies Ignore Aging-at-Home Concept 2Medicare Policies Ignore Aging-at-Home Concept 3Medicare Policies Ignore Aging-at-Home Concept 4Medicare Policies Ignore Aging-at-Home Concept 5
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... Recently, BellasDress has launched its ... dresses. BellasDress has chosen their best-selling lace wedding dresses, ... the holiday season. , Now, BellasDress.com features popular ... here at discount prices. The business hopes everyone can ... , “All our elegant products are made ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... The risk of burns from fires and cooking accidents ... extra cautious, an expert says. "Between Thanksgiving and ... patients coming in with burns," said Dr. Steven Sandoval, ... Center of Stony Brook University Hospital in New York. ... if not careful, could quickly turn tragic," Sandoval said ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2
... Change Student Behavior, BOCA RATON, Fla., Oct. 25 ... sanitizer to help,prevent the spread of germs including the ... hand-to-hand contact, has resulted in the death,of at least ... ill,across the country. The Centers for Disease Control recently ...
... by researchers at the Yale Stem Cell Center for ... class of tiny RNAs, play an important role in ... Nature. , Haifan Lin, director of the stem cell ... of Medicine, heads the laboratory that originally identified piRNAs. ...
... will join more than 100 leading public figures, philanthropists ... New York on 29 October to mark the launch ... US based National Foundation for Cancer Research (NFCR). Through ... Fund at NFCR, Americans can support the IAEA and ...
... Oct. 25 Losing the ability to see, ... steadfast person. Despite,horrific obstacles like these, some plastic ... to inspire and help others in need.,A.J. Reed ... will,be honored with the Patients of Courage: Triumph ...
... MESA, Calif., Oct. 25 CNS Response,Inc. (OTC ... conducted a,quality assurance analysis of its current multi-center ... Based on the evaluation, CNS Response is amending ... issues related to functionality and,operability. Changes to ...
... Net Loss Narrows on Growth of Services Revenues, Higher ... Months; Outlook Improves for 2007 Net Results, POWAY, ... a leading provider of medical diagnostic imaging systems,and services ... losses for the third quarter and nine months ended,September ...
Cached Medicine News:Health News:SafeHands' School Program to Help Fight Spread of MRSA Staph Virus 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Amarillo Native Honored for Courage, Selflessness 2Health News:CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study 2Health News:CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study 3Health News:CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study 4Health News:CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study 5Health News:CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study 6Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 2Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 3Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 4Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 5Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 6Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 7Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 8Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 9
... Clarity Classmate video magnifier (model CLCM) was ... has the need to see objects at a ... The Classmate's rotating camera design allows viewing at ... easy to switch between near and distant viewing. ...
... portability together in one product. Flipperport consists ... color camera that captures the image, and ... the magnified image. This self contained, battery-operated ... and comfort. FlipperPort can easily connect with ...
... vision to see objects at a distance, ... between. This battery operated system can be ... used as a desktop video magnifier when ... easy to use and requires no special ...
... incubators designed to provide the ... required for the most demanding ... controlled incubators feature push-button temperature ... display, and built-in over-temperature protection. ...
Medicine Products: